Plexon Inc Celebrates 30 Years in Neuroscience Research, Record Sales and a New Website
News Jan 30, 2013
Today's celebration unleashes bold new branding, a completely redesigned website, the company's first publication grant contest, product promotions, marketing programs and extended service hours.
Decades ago, Harvey Wiggins, Plexon's president, designed the industry's first high channel count data acquisition system to more effectively facilitate the recording and analysis of brain signals. Today, Plexon proudly serves thousands of customers in nearly 40 countries. Plexon thrived in 2012 closing double digit growth that yielded record sales. To meet increasing demand, Plexon grew its employee base by nearly 30%. Its stats are especially impressive considering the disappointing ~2% growth of the U.S. economy, and the hardly better ~4% growth of the U.S. scientific research and development market.
To punctuate its strength and long-term vision, Plexon launched a bold new look and a top tier website providing exceptionally easy-to-navigate, open access to a wealth of content. Further, Plexon is offering two rare promotions for its Offline Sorter (OFS), the most trusted offline spike sorting software cited in more than 800 publications. When purchasing OFS, researchers may choose either an extra license key (a $2,000+ value), or special pricing (nearly a $1,000 value).
As part of the celebration and in partnership with the Journal of Visualized Experiments (JoVE), Plexon announces the first Publication Grant Contest -- valued at $4,200. Researchers are encouraged to submit abstracts about research performed using the OmniPlex® Neural Data Acquisition System. The winner's research will be peer-reviewed, published in video and text formats, and freely accessible at www.jove.com.
LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target DiscoveryNews
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.READ MORE
Drug-like Compounds Reverse Chemotherapy Failure for 3 Aggressive CancersNews
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers -- ovarian, prostate and breast.READ MORE
Algorithm Unearths Over 1000 Antibiotic Proteins in a Few HoursNews
The algorithm identified 10 times more peptide variations than all previous discoveries combined, aiding the hunt for new antibiotics.READ MORE